title: Systemic therapy of primary cutaneous B-cell lymphoma, marginal zone type, with rituximab, a chimeric anti-CD20 monoclonal antibody.
authors.forename: R
authors.initials: R
authors.lastname: Soda
authors.forename: A
authors.initials: A
authors.lastname: Costanzo
authors.forename: M
authors.initials: M
authors.lastname: Cantonetti
authors.forename: A
authors.initials: A
authors.lastname: Orlandi
authors.forename: L
authors.initials: L
authors.lastname: Bianchi
authors.forename: S
authors.initials: S
authors.lastname: Chimenti
mesh_terms: D000328:Adult; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D006801:Humans; D016393:Lymphoma, B-Cell / Q000473:pathology / Q000628:therapy*; D008297:Male; D000069283:Rituximab; D012878:Skin Neoplasms / Q000473:pathology / Q000628:therapy*
chemical_list: D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D000069283:Rituximab